Coskun Mehmet
Department of Radiology, Baskent University, Ankara, Turkey.
Exp Clin Transplant. 2017 Mar;15(Suppl 2):36-44. doi: 10.6002/ect.TOND16.L10.
Hepatocellular carcinoma is the fifth most common tumor in patients worldwide and the third most common cause of cancer-related death, after lung and stomach cancer. Cirrhosis of the liver is the strongest predisposing factor for hepatocellular carcinoma, with approximately 80% of cases of hepatocellular carcinoma developing in a cirrhotic liver. The annual incidence of hepatocellular carcinoma is 2.0% to 6.6% in patients with cirrhosis compared with 0.4% in patients without cirrhosis. The 5-year survival rates of patients undergoing curative therapies for hepatocellular carcinoma, including liver transplant, hepatic resection, and percutaneous ablative techniques, range between 40% and 75%. Orthotropic liver transplant offers the prima facie cure for both hepatocellular carcinoma and liver cirrhosis. In hepatocellular carcinoma confined to the liver without macrovascular invasion, patients with a single tumor ≤ 5 cm or up to 3 tumors ≤ 3 cm each had a 5-year survival rate of 75% and a disease-free survival rate of 83%. In the adult population, liver transplant for hepatocellular carcinoma yields good results for patients whose tumor masses do not exceed the Milan criteria. The diagnosis of hepatocellular carcinoma using imaging tests has had a substantial impact on transplant decisions. Radiologists should be aware of this responsibility and exercise the utmost scrutiny before making a diagnosis of hepatocellular carcinoma. Erroneous diagnosis of hepatocellular carcinoma based on imaging tests could deny deserving patients the opportunity of a life-saving liver transplant and result in unnecessary liver transplants for others. Contrast-enhanced magnetic resonance imaging and helical computed tomography are the best imaging techniques currently available for the noninvasive diagnosis of hepatocellular carcinoma. With technological advances in hardware and software, diffusion-weighted imaging can be readily applied to the liver with resulting improved image quality.
肝细胞癌是全球患者中第五大常见肿瘤,也是癌症相关死亡的第三大常见原因,仅次于肺癌和胃癌。肝硬化是肝细胞癌最强的诱发因素,约80%的肝细胞癌病例发生在肝硬化肝脏中。肝硬化患者肝细胞癌的年发病率为2.0%至6.6%,而无肝硬化患者的年发病率为0.4%。接受肝细胞癌根治性治疗(包括肝移植、肝切除和经皮消融技术)的患者5年生存率在40%至75%之间。原位肝移植为肝细胞癌和肝硬化提供了初步的治愈方法。对于局限于肝脏且无大血管侵犯的肝细胞癌患者,单个肿瘤≤5 cm或最多3个肿瘤、每个肿瘤≤3 cm的患者5年生存率为75%,无病生存率为83%。在成年人群中,对于肿瘤肿块未超过米兰标准的肝细胞癌患者,肝移植取得了良好的效果。使用影像学检查诊断肝细胞癌对移植决策产生了重大影响。放射科医生应意识到这一责任,并在做出肝细胞癌诊断之前进行最严格的检查。基于影像学检查对肝细胞癌的错误诊断可能会使应得的患者失去接受挽救生命的肝移植的机会,并导致其他患者接受不必要的肝移植。对比增强磁共振成像和螺旋计算机断层扫描是目前可用于肝细胞癌无创诊断的最佳影像学技术。随着硬件和软件技术的进步,扩散加权成像可以很容易地应用于肝脏,从而提高图像质量。